Journal of Virology

• 

  Publication Venue For

  • A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques..  94. 2020
  • Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees..  93. 2019
  • Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape.  92. 2018
  • Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors..  90:4215-4231. 2016
  • Particle-to-PFU Ratio of Ebola Virus Influences Disease Course and Survival in Cynomolgus Macaques.  89:6773-6781. 2015
  • Correction to Heavy Chain-Only IgG2b Llama antibody effects Near-Pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites [Journal of Virology 87, 18, (2013) 10173-10181].  89:883-885. 2015
  • Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography..  88:10958-10962. 2014
  • HIV-1 envelope glycoprotein trimers display open quaternary conformation when bound to the gp41 membrane-proximal external-region-directed broadly neutralizing antibody Z13e1..  87:7191-7196. 2013
  • Utilization of Sialylated Glycans as Coreceptors Enhances the Neurovirulence of Serotype 3 Reovirus.  86:13164-13173. 2012
  • The Reovirus  1s Protein Is a Determinant of Hematogenous but Not Neural Virus Dissemination in Mice.  85:11781-11790. 2011
  • The NLRP3 inflammasome detects encephalomyocarditis virus and vesicular stomatitis virus infection..  85:4167-4172. 2011
  • Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry.  85:8270-8284. 2011
  • Impact of HLA in mother and child on disease progression of pediatric human immunodeficiency virus type 1 infection..  83:10234-10244. 2009
  • Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo..  83:7706-7717. 2009
  • Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants (Journal of Virology (2009) 83, 8, (3556-3567)).  83:6974. 2009
  • Analysis of the interaction of primate retroviruses with the human RNA interference machinery..  81:12218-12226. 2007
  • Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles..  81:10869-10878. 2007
  • Murine noroviruses comprising a single genogroup exhibit biological diversity despite limited sequence divergence..  81:10460-10473. 2007
  • Erratum: Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection (Journal of Virology (2006) 80, 22, (11094-11104)).  81:8846-8848. 2007
  • Genetic adaptation to untranslated region-mediated enterovirus growth deficits by mutations in the nonstructural proteins 3AB and 3CD..  81:8396-8405. 2007
  • Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors..  81:8563-8570. 2007
  • Memory CD4+ T-lymphocyte loss and dysfunction during primary simian immunodeficiency virus infection..  81:8009-8015. 2007
  • Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo..  81:7540-7547. 2007
  • Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees..  81:7463-7475. 2007
  • Location and role of free cysteinyl residues in the Sindbis virus E1 and E2 glycoproteins..  81:6231-6240. 2007
  • The DNA binding domain of a papillomavirus E2 protein programs a chimeric nuclease to cleave integrated human papillomavirus DNA in HeLa cervical carcinoma cells..  81:6254-6264. 2007
  • Antiviral antibodies are necessary for control of simian immunodeficiency virus replication..  81:5024-5035. 2007
  • Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques..  81:5257-5269. 2007
  • A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques..  81:3414-3427. 2007
  • Evolutionary insights into the ecology of coronaviruses..  81:4012-4020. 2007
  • Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity..  81:3487-3494. 2007
  • Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo..  81:1796-1812. 2007
  • Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements..  81:791-799. 2007
  • Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis..  81:74-83. 2007
  • Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa..  80:11776-11790. 2006
  • Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag..  80:12095-12101. 2006
  • The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles..  80:12102-12108. 2006
  • Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection..  80:11094-11104. 2006
  • Human papillomavirus genotype 31 does not express detectable microRNA levels during latent or productive virus replication..  80:10890-10893. 2006
  • Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes..  80:11393-11397. 2006
  • Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry..  80:8961-8969. 2006
  • Integration Site Choice of a Feline Immunodeficiency Virus Vector.  80:8820-8823. 2006
  • Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages..  80:9200-9206. 2006
  • Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death..  80:9300-9309. 2006
  • Prevalence and genetic diversity of coronaviruses in bats from China..  80:7481-7490. 2006
  • Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen..  80:6745-6756. 2006
  • Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques..  80:6399-6410. 2006
  • The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site..  80:6936-6942. 2006
  • A novel assay for viral microRNA function identifies a single nucleotide polymorphism that affects Drosha processing..  80:5321-5326. 2006
  • Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76..  80:3147-3156. 2006
  • Competitive translation efficiency at the picornavirus type 1 internal ribosome entry site facilitated by viral cis and trans factors..  80:3310-3321. 2006
  • Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels..  80:3732-3742. 2006
  • Transcriptional origin of Kaposi's sarcoma-associated herpesvirus microRNAs..  80:2234-2242. 2006
  • Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env..  80:1645-1652. 2006
  • Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors..  80:1067-1076. 2006
  • A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease..  79:15356-15367. 2005
  • Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization..  79:14804-14814. 2005
  • Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages..  79:13250-13261. 2005
  • Effect of alternating passage on adaptation of sindbis virus to vertebrate and invertebrate cells..  79:14253-14260. 2005
  • Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain..  79:13338-13349. 2005
  • Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope..  79:11214-11224. 2005
  • Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66..  79:11014-11021. 2005
  • Variation in interferon sensitivity and induction among strains of eastern equine encephalitis virus..  79:11300-11310. 2005
  • Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies..  79:10108-10125. 2005
  • Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies..  79:10200-10209. 2005
  • DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge..  79:8480-8492. 2005
  • Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion..  79:8201-8207. 2005
  • Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques..  79:8131-8141. 2005
  • Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins..  79:8189-8200. 2005
  • Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors..  79:8724-8731. 2005
  • Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses..  79:8878-8885. 2005
  • Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1..  79:7933-7937. 2005
  • Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells..  79:6281-6290. 2005
  • The polypyrimidine tract binding protein is required for efficient picornavirus gene expression and propagation..  79:6172-6179. 2005
  • Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells..  79:3358-3369. 2005
  • Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2..  79:3243-3253. 2005
  • Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein..  79:1154-1163. 2005
  • Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins..  79:771-779. 2005
  • Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques..  79:955-965. 2005
  • Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis..  78:12868-12876. 2004
  • Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus..  78:13819-13828. 2004
  • Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting..  78:13163-13172. 2004
  • Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque..  78:13455-13459. 2004
  • Further investigation of simian immunodeficiency virus Vif function in human cells..  78:12041-12046. 2004
  • Impact on genetic networks in human macrophages by a CCR5 strain of human immunodeficiency virus type 1..  78:11477-11486. 2004
  • Genetic relationships and evolution of genotypes of yellow fever virus and other members of the yellow fever virus group within the Flavivirus genus based on the 3' noncoding region..  78:9652-9665. 2004
  • Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody..  78:9233-9242. 2004
  • Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys..  78:7490-7497. 2004
  • New simian immunodeficiency virus infecting De Brazza's monkeys (Cercopithecus neglectus): evidence for a cercopithecus monkey virus clade..  78:7748-7762. 2004
  • Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies..  78:5983-5995. 2004
  • Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups..  78:4421-4432. 2004
  • Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins..  78:5270-5278. 2004
  • Inability of Simian Virus 40 To Establish Productive Infection of Lymphoblastic Cell Lines.  78:4917-4920. 2004
  • Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques..  78:3561-3571. 2004
  • Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol..  78:3930-3940. 2004
  • Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells..  78:4063-4073. 2004
  • Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious..  78:2426-2433. 2004
  • Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques..  78:275-284. 2004
  • Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation..  78:922-929. 2004
  • Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239..  77:13348-13360. 2003
  • Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector..  77:11964-11972. 2003
  • Structure and function of CC-chemokine receptor 5 homologues derived from representative primate species and subspecies of the taxonomic suborders Prosimii and Anthropoidea..  77:12310-12318. 2003
  • Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies..  77:10348-10356. 2003
  • Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity..  77:10819-10828. 2003
  • Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate..  77:11244-11259. 2003
  • Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen..  77:8354-8365. 2003
  • Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses..  77:9029-9040. 2003
  • Foci of endemic simian immunodeficiency virus infection in wild-living eastern chimpanzees (Pan troglodytes schweinfurthii)..  77:7545-7562. 2003
  • Increased thymic output during acute measles virus infection..  77:7872-7879. 2003
  • CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition..  77:6777-6784. 2003
  • Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene..  77:6743-6752. 2003
  • RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells..  77:6066-6069. 2003
  • Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys..  77:4396-4400. 2003
  • Loss of the perforin cytotoxic pathway predisposes mice to experimental cytomegalovirus retinitis..  77:3402-3408. 2003
  • Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses..  77:3099-3118. 2003
  • Amplification of a complete simian immunodeficiency virus genome from fecal RNA of a wild chimpanzee..  77:2233-2242. 2003
  • Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus..  77:2165-2173. 2003
  • Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d..  77:2046-2055. 2003
  • Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages..  77:2539-2549. 2003
  • Glycosaminoglycan binding properties of natural venezuelan equine encephalitis virus isolates..  77:1204-1210. 2003
  • Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production..  77:423-432. 2003
  • Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine..  77:1049-1058. 2003
  • Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes..  77:546-559. 2003
  • Identification of the orthopoxvirus p4c gene, which encodes a structural protein that directs intracellular mature virus particles into A-type inclusions..  76:11216-11225. 2002
  • Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251..  76:11365-11378. 2002
  • Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry..  76:11236-11244. 2002
  • Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection..  76:10507-10511. 2002
  • Elevated chemokine responses are maintained in lungs after clearance of viral infection..  76:10518-10523. 2002
  • In Vivo Gene Transfer Using a Nonprimate Lentiviral Vector Pseudotyped with Ross River Virus Glycoproteins.  76:9378-9388. 2002
  • Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer..  76:8769-8775. 2002
  • Genetically stable picornavirus expression vectors with recombinant internal ribosomal entry sites..  76:8966-8972. 2002
  • Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference..  76:9225-9231. 2002
  • Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines..  76:7625-7631. 2002
  • Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1..  76:8276-8284. 2002
  • Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239..  76:7187-7202. 2002
  • Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine..  76:6138-6146. 2002
  • Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization..  76:5357-5368. 2002
  • Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage..  76:5278-5284. 2002
  • Recruitment of the Crm1 nuclear export factor is sufficient to induce cytoplasmic expression of incompletely spliced human immunodeficiency virus mRNAs..  76:2036-2042. 2002
  • Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa..  76:2233-2244. 2002
  • A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation..  76:569-581. 2002
  • ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency..  76:292-302. 2002
  • Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization..  76:517-524. 2002
  • Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia..  76:397-405. 2002
  • Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques..  76:96-104. 2002
  • NF-kappaB cis-acting motifs of the human immunodeficiency virus (HIV) long terminal repeat regulate HIV transcription in human macrophages..  75:11408-11416. 2001
  • Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection..  75:10200-10207. 2001
  • Jaagsiekte Sheep Retrovirus Env Protein Stabilizes Retrovirus Vectors against Inactivation by Lung Surfactant, Centrifugation, and Freeze-Thaw Cycling.  75:8864-8867. 2001
  • Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines..  75:8681-8689. 2001
  • Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors..  75:7266-7279. 2001
  • Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates..  75:6776-6785. 2001
  • Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge..  75:7470-7480. 2001
  • The R region found in the human foamy virus long terminal repeat is critical for both Gag and Pol protein expression..  75:6817-6824. 2001
  • Wild Mandrillus sphinx are carriers of two types of lentivirus..  75:7086-7096. 2001
  • Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate..  75:6700-6704. 2001
  • Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques..  75:5879-5890. 2001
  • Potential sources of the 1995 Venezuelan equine encephalitis subtype IC epidemic..  75:5823-5832. 2001
  • Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination..  75:5151-5158. 2001
  • Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope..  75:4165-4175. 2001
  • RNA replication from the simian virus 5 antigenomic promoter requires three sequence-dependent elements separated by sequence-independent spacer regions..  75:3993-3998. 2001
  • Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques..  75:2224-2234. 2001
  • Functional analysis of the simian immunodeficiency virus Vpx protein: identification of packaging determinants and a novel nuclear targeting domain..  75:362-374. 2001
  • Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140..  75:645-653. 2001
  • In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail..  75:278-291. 2001
  • Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions..  74:10514-10522. 2000
  • Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells..  74:9868-9877. 2000
  • Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen..  74:8946-8952. 2000
  • Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate..  74:9749-9754. 2000
  • Mutational definition of functional domains within the Rev homolog encoded by human endogenous retrovirus K..  74:9353-9361. 2000
  • Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses..  74:6984-6991. 2000
  • Overexpression of p21(waf1) in human T-cell lymphotropic virus type 1-infected cells and its association with cyclin A/cdk2..  74:7270-7283. 2000
  • Analysis of cellular factors that mediate nuclear export of RNAs bearing the Mason-Pfizer monkey virus constitutive transport element..  74:5863-5871. 2000
  • Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1..  74:5040-5052. 2000
  • Clinical isolates of measles virus use CD46 as a cellular receptor..  74:3967-3974. 2000
  • Functional differences between human and bovine immunodeficiency virus Tat transcription factors..  74:4666-4671. 2000
  • Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses..  74:3227-3234. 2000
  • Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques..  74:2960-2965. 2000
  • Characterization of the trans-activation properties of equine herpesvirus 1 EICP0 protein..  74:1200-1208. 2000
  • Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains..  74:254-263. 2000
  • Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles..  74:371-378. 2000
  • Characterization of primary isolate-like variants of simian-human immunodeficiency virus..  73:10199-10207. 1999
  • Protection by live, attenuated simian immunodeficiency virus against heterologous challenge..  73:8356-8363. 1999
  • Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques..  73:8201-8215. 1999
  • Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes..  73:5777-5786. 1999
  • Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection..  73:5509-5519. 1999
  • Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation..  73:4952-4961. 1999
  • Genetic and phenotypic changes accompanying the emergence of epizootic subtype IC Venezuelan equine encephalitis viruses from an enzootic subtype ID progenitor..  73:4266-4271. 1999
  • Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines..  73:3134-3146. 1999
  • Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction..  73:2569-2575. 1999
  • Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence..  73:958-964. 1999
  • Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen..  73:618-630. 1999
  • Nuclear magnetic resonance analysis of solution conformations in C4-V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: relation to specificity of peptide-induced anti-HIV neutralizing antibodies..  73:746-750. 1999
  • RNA replication for the paramyxovirus simian virus 5 requires an internal repeated (CGNNNN) sequence motif..  73:805-809. 1999
  • An isolate of human immunodeficiency virus type 1 originally classified as subtype I represents a complex mosaic comprising three different group M subtypes (A, G, and I)..  72:10234-10241. 1998
  • Localization of a baculovirus-induced chitinase in the insect cell endoplasmic reticulum..  72:10207-10212. 1998
  • A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element (vol 72, pg 5638, 1998).  72:9419-9419. 1998
  • Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1..  72:8627-8635. 1998
  • Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting..  72:9092-9100. 1998
  • Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine..  72:7501-7509. 1998
  • Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus..  72:6950-6955. 1998
  • Viral genetic evolution in macaques infected with molecularly cloned simian immunodeficiency virus correlates with the extent of persistent viremia..  72:6482-6489. 1998
  • A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1..  72:5680-5698. 1998
  • A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element..  72:5638-5647. 1998
  • Derivation and functional characterization of a consensus DNA binding sequence for the tas transcriptional activator of simian foamy virus type 1..  72:5502-5509. 1998
  • Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry..  72:5425-5432. 1998
  • Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1..  72:4962-4969. 1998
  • Mechanism of injury-provoked poliomyelitis..  72:5056-5060. 1998
  • Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure..  72:4170-4182. 1998
  • CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes..  72:3129-3137. 1998
  • Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1..  72:3427-3431. 1998
  • Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage..  72:1886-1893. 1998
  • Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates..  72:1918-1924. 1998
  • Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines..  72:1552-1576. 1998
  • Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted..  72:926-933. 1998
  • A functional antigenomic promoter for the paramyxovirus simian virus 5 requires proper spacing between an essential internal segment and the 3' terminus..  72:10-19. 1998
  • Erratum: A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element (Journal of Virology (1998) 72:7 (5638-5647)).  72:9419. 1998
  • Identification and functional characterization of a high-affinity Bel-1 DNA binding site located in the human foamy virus internal promoter..  72:504-511. 1998
  • Natural infection of a household pet red-capped mangabey (Cercocebus torquatus torquatus) with a new simian immunodeficiency virus..  72:600-608. 1998
  • Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque..  72:585-592. 1998
  • Rotavirus RNA polymerase requires the core shell protein to synthesize the double-stranded RNA genome..  71:9618-9626. 1997
  • Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians..  71:8908-8911. 1997
  • Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus Nef use distinct but overlapping target sites for downregulation of cell surface CD4..  71:6742-6748. 1997
  • Murine CXCR-4 is a functional coreceptor for T-cell-tropic and dual-tropic strains of human immunodeficiency virus type 1..  71:7097-7100. 1997
  • Molecular analysis of the feline immunodeficiency virus protease: generation of a novel form of the protease by autoproteolysis and construction of cleavage-resistant proteases..  71:5505-5511. 1997
  • The ICP0 protein of equine herpesvirus 1 is an early protein that independently transactivates expression of all classes of viral promoters..  71:4904-4914. 1997
  • Genetic diversity of feline immunodeficiency virus: dual infection, recombination, and distinct evolutionary rates among envelope sequence clades..  71:4241-4253. 1997
  • Evolution and probable transmission of intersubtype recombinant human immunodeficiency virus type 1 in a Zambian couple..  71:2647-2655. 1997
  • Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells..  71:2512-2517. 1997
  • A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3..  71:1608-1620. 1997
  • Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3..  71:1213-1219. 1997
  • Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition..  71:1256-1264. 1997
  • The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin..  70:7013-7029. 1996
  • Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses..  70:6136-6142. 1996
  • Inhibition of nitric oxide synthesis increases mortality in Sindbis virus encephalitis..  70:3972-3977. 1996
  • Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara..  70:3741-3752. 1996
  • Simian immunodeficiency virus DNA vaccine trial in macaques..  70:3978-3991. 1996
  • The human foamy virus Bel-1 transcription factor is a sequence-specific DNA binding protein..  70:3902-3908. 1996
  • Vaccine protection by a triple deletion mutant of simian immunodeficiency virus..  70:3724-3733. 1996
  • An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys..  70:3198-3206. 1996
  • n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes..  70:2691-2696. 1996
  • Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization..  70:1651-1667. 1996
  • Sequences within a small yeast RNA required for inhibition of internal initiation of translation: interaction with La and other cellular proteins influences its inhibitory activity..  70:1624-1632. 1996
  • Sequences flanking the pentanucleotide T-antigen binding sites in the polyomavirus core origin help determine selectivity of DNA replication..  69:7570-7578. 1995
  • Immunogenic determinants of a neuropathogenic murine leukemia virus..  69:6847-6851. 1995
  • Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers..  69:5988-5994. 1995
  • Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat..  69:6572-6576. 1995
  • Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1..  69:6239-6248. 1995
  • A human recombinant Fab identifies a human immunodeficiency virus type 1-induced conformational change in cell surface-expressed CD4..  69:5734-5742. 1995
  • Cellular CD44S as a determinant of human immunodeficiency virus type 1 infection and cellular tropism..  69:4000-4005. 1995
  • A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion..  69:3771-3777. 1995
  • Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors..  69:3098-3107. 1995
  • Direct interactions between autoantigen La and human immunodeficiency virus leader RNA..  69:618-619. 1995
  • Direct interactions between autoantigen La and human immunodeficiency virus leader RNA..  68:7008-7020. 1994
  • Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology..  68:7433-7447. 1994
  • Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge..  68:6578-6588. 1994
  • Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins..  68:5685-5689. 1994
  • Genetic analysis indicates that the human foamy virus Bel-1 protein contains a transcription activation domain of the acidic class..  68:3803-3808. 1994
  • Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes..  68:3410-3414. 1994
  • Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques..  68:2362-2370. 1994
  • Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein..  68:2624-2631. 1994
  • T-antigen kinase inhibits simian virus 40 DNA replication by phosphorylation of intact T antigen on serines 120 and 123..  68:269-275. 1994
  • Identification of the activation domain of equine infectious anemia virus rev..  67:7317-7323. 1993
  • Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element..  67:6882-6888. 1993
  • Transcriptional trans activators of human and simian foamy viruses contain a small, highly conserved activation domain..  67:6824-6827. 1993
  • Phenotypic and functional consequences of herpesvirus saimiri infection of human CD8+ cytotoxic T lymphocytes..  67:6317-6321. 1993
  • Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus type 1 in cells..  67:5617-5622. 1993
  • Genetic evidence that the Tat proteins of human immunodeficiency virus types 1 and 2 can multimerize in the eukaryotic cell nucleus..  67:5030-5034. 1993
  • Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function..  67:3703-3711. 1993
  • Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo..  67:3951-3960. 1993
  • Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells..  67:4062-4069. 1993
  • La autoantigen enhances and corrects aberrant translation of poliovirus RNA in reticulocyte lysate..  67:3798-3807. 1993
  • Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein..  67:3615-3619. 1993
  • Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21)..  67:2699-2706. 1993
  • Functional organization of the Bel-1 trans activator of human foamy virus..  67:1896-1904. 1993
  • The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks..  67:1218-1226. 1993
  • Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus..  67:613-616. 1993
  • Plasmid models for bacteriophage T4 DNA replication: requirements for fork proteins..  66:6960-6968. 1992
  • Specific binding of the human T-cell leukemia virus type I Rex protein to a short RNA sequence located within the Rex-response element..  66:7572-7575. 1992
  • Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins..  66:5879-5889. 1992
  • Comparative analysis of Rev function in human immunodeficiency virus types 1 and 2..  66:4288-4294. 1992
  • In vivo genetic variability of the human immunodeficiency virus type 2 V3 region..  66:4546-4550. 1992
  • The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro..  66:4085-4097. 1992
  • Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types..  66:3971-3975. 1992
  • Structural and functional analysis of the visna virus Rev-response element..  66:3609-3615. 1992
  • The Bel-1 protein of human foamy virus activates human immunodeficiency virus type 1 gene expression via a novel DNA target site..  66:3946-3949. 1992
  • Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41..  66:1799-1803. 1992
  • Unusual structure of the human immunodeficiency virus type 1 trans-activation response element..  66:930-935. 1992
  • Analysis of trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism..  65:6922-6930. 1991
  • Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation..  65:6811-6816. 1991
  • Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells..  65:6008-6014. 1991
  • Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity..  65:6349-6352. 1991
  • Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages..  65:4309-4316. 1991
  • Mutational definition of the human immunodeficiency virus type 1 Rev activation domain..  65:4248-4254. 1991
  • Conserved functional organization of the human immunodeficiency virus type 1 and visna virus Rev proteins..  65:3877-3881. 1991
  • Efficient polyadenylation within the human immunodeficiency virus type 1 long terminal repeat requires flanking U3-specific sequences..  65:3340-3343. 1991
  • Characterization of the transcriptional trans activator of human foamy retrovirus..  65:2589-2594. 1991
  • Effects of chimeric mutants of human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex on nucleolar targeting signals..  65:2452-2456. 1991
  • Protein phosphatase 2A dephosphorylates simian virus 40 large T antigen specifically at residues involved in regulation of DNA-binding activity..  65:2098-2101. 1991
  • Human immunodeficiency virus as a prototypic complex retrovirus..  65:1053-1056. 1991
  • Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products..  65:1653-1657. 1991
  • Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus..  64:5223-5225. 1990
  • Kinetics of poliovirus uncoating in HeLa cells in a nonacidic environment..  64:3590-3597. 1990
  • Association of p62c-yes with polyomavirus middle T-antigen mutants correlates with transforming ability..  64:1584-1589. 1990
  • Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques..  64:113-119. 1990
  • Structure and orientation of expressed bovine coronavirus hemagglutinin-esterase protein.  64:1834-1838. 1990
  • Functional analysis of the Tat trans activator of human immunodeficiency virus type 2..  63:5006-5012. 1989
  • Transcription of a poxvirus early gene is regulated both by a short promoter element and by a transcriptional termination signal controlling transcriptional interference..  63:4632-4644. 1989
  • Viral transcription is necessary and sufficient for vesicular stomatitis virus to inhibit maturation of small nuclear ribonucleoproteins..  63:4172-4180. 1989
  • Functional characterization of a complex protein-DNA-binding domain located within the human immunodeficiency virus type 1 long terminal repeat leader region..  63:3213-3219. 1989
  • Development and characterization of an Fv-1-sensitive retrovirus-packaging system: single-hit titration kinetics observed in restrictive cells..  63:2592-2597. 1989
  • Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein..  63:1181-1187. 1989
  • The second-largest subunit of the poxvirus RNA polymerase is similar to the corresponding subunits of procaryotic and eucaryotic RNA polymerases..  63:1076-1086. 1989
  • Cellular gene expression in papillomas of the choroid plexus from transgenic mice that express the simian virus 40 large T antigen..  63:790-797. 1989
  • Identification of a U5-specific sequence required for efficient polyadenylation within the human immunodeficiency virus long terminal repeat..  63:421-424. 1989
  • Phosphorylation of the rev gene product of human immunodeficiency virus type 1..  62:4801-4804. 1988
  • Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4..  62:4195-4200. 1988
  • Subcellular localization of the human immunodeficiency virus trans-acting art gene product..  62:2498-2501. 1988
  • Simian virus 40 (SV40) T antigen binds specifically to double-stranded DNA but not to single-stranded DNA or DNA/RNA hybrids containing the SV40 regulatory sequences..  62:2204-2208. 1988
  • Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat..  62:673-679. 1988
  • Fine mapping two distinct antigenic sites on simian virus 40 (SV40) T antigen reactive with SV40-specific cytotoxic T-cell clones by using SV40 deletion mutants..  62:285-296. 1988
  • Retroviral vector gene expression in F9 embryonal carcinoma cells..  61:3248-3253. 1987
  • Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection..  61:2017-2023. 1987
  • Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice..  61:2029-2032. 1987
  • Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert..  61:1193-1202. 1987
  • Lack of evidence for VPg priming of poliovirus RNA synthesis in the host factor-dependent in vitro replicase reaction..  58:212-215. 1986
  • Effect of herpes simplex virus types 1 and 2 on surface expression of class I major histocompatibility complex antigens on infected cells..  56:757-766. 1985
  • Selectivity of interferon action in simian virus 40-transformed cells superinfected with simian virus 40..  53:893-898. 1985
  • Transcriptional activity of avian retroviral long terminal repeats directly correlates with enhancer activity..  53:515-521. 1985
  • Fusion of the termini of the murine cytomegalovirus genome after infection..  52:24-28. 1984
  • Sites of copy choice replication involved in generation of vesicular stomatitis virus defective-interfering particle RNAs..  51:515-521. 1984
  • Nucleotide sequence and host La protein interactions of rabies virus leader RNA..  50:773-778. 1984
  • Revertants and partial transformants of rat fibroblasts infected with Fujinami sarcoma virus..  50:325-334. 1984
  • Cytoplasmic localization of the transforming protein of Fujinami sarcoma virus: salt-sensitive association with subcellular components..  45:782-791. 1983
  • RNA polymerase-associated interactions near template promoter sequences of defective interfering particles of vesicular stomatitis virus..  43:241-249. 1982
  • Polyoma virus infection of retinoic acid-induced differentiated teratocarcinoma cells..  39:306-312. 1981
  • Mutants of Fujinami sarcoma virus which are temperature sensitive for cellular transformation and protein kinase activity..  38:347-355. 1981
  • Simian virus 40 transcriptional complexes incorporate mercurated nucleotides into RNA in vitro..  37:511-517. 1981
  • Site on the vesicular stomatitis virus genome specifying polyadenylation and the end of the L gene mRNA..  34:550-559. 1980
  • Intervening sequence between the leader region and the nucleopcapsid gene of vesicular stomatitis virus RNA..  33:789-794. 1980
  • Terminal sequences of vesicular stomatitis virus RNA are both complementary and conserved..  32:167-174. 1979
  • Topography of a flexible ribonucleoprotein helix: protein-protein contacts in Sendai virus nucleocapsids..  30:701-710. 1979
  • Evidence that a precursor glycoprotein is cleaved to yield the major glycoprotein of avian tumor virus..  21:810-814. 1977
  • Interspecies determinants of Friend leukemia virus antigens involved in cytolysis of virus-pfoducing cells..  21:113-118. 1977
  • Role of carbohydrate in biological functions of Friend murine leukemia virus gp71..  21:35-40. 1977
  • Viral glycoprotein synthesis studies in an established line of Japanese quail embryo cells infected with the Bryan high-titer strain of Rous sarcoma virus..  18:504-510. 1976
  • Purification and serological characterization of the major envelope glycoprotein from AKR murine leukemia virus and its reactivity with autogenous immune sera from mice..  17:727-736. 1976
  • Role of carbohydrate in determining the immunochemical properties of the major glycoprotein (gp71) of Friend murine leukemia virus..  16:1453-1463. 1975
  • Mitosis is required for production of murine leukemia virus and structural proteins during de novo infection..  16:267-274. 1975
  • Expression of the Major Viral Glycoprotein of Avian Tumor Virus in Cells of chf(+) Chicken Embryos..  15:1131-1140. 1975
  • Isolation of two subgroup-specific leukemogenic viruses from standard avian myeloblastosis virus..  15:906-912. 1975
  • Reactivity of avian RNA tumor viruses with lectins..  17:132-139. 1975
  • Outer membrane of avian myeloblastosis virus..  12:1579-1588. 1973
  • Multiple and specific initiation of T4 DNA replication..  12:130-148. 1973
  • Early intracellular events in the replication of bacteriophage T4 deoxyribonucleic acid. VI. Newly synthesized proteins in the T4 protein-deoxyribonucleic acid complex..  5:502-506. 1970
  • In vitro chick embryo cell response to strain MC29 avian leukosis virus..  2:576-586. 1968
  • Erratum to Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies [Journal of Virology, 85, 21, (2011) 11401-11408] DOI: 10.1128/JVI.05312-11.  87:13936. 2013
  • Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection (Journal of Virology (2009) 83, 3, (1422-1432)).  83:8297. 2009
  • Partial protection of simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate (Journal of Virology (2009) 83, 6 (2686-2696)).  83:5293. 2009
  • Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines..  79:10103-10107. 2005
  • Erratum: Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles (Journal of Virology (2000) 74:1 (371-378)).  74:3430. 2000